Human
chymotrypsin C (CTRC) protects against
pancreatitis by degrading
trypsinogen and thereby curtailing harmful intra-pancreatic
trypsinogen activation. Loss-of-function mutations in CTRC increase the risk for
chronic pancreatitis. Here we describe functional analysis of eight previously uncharacterized natural CTRC variants tested for potential defects in secretion, proteolytic stability, and catalytic activity. We found that all variants were secreted from transfected cells normally, and none suffered proteolytic degradation by
trypsin. Five variants had normal enzymatic activity, whereas variant p.R29Q was catalytically inactive due to loss of activation by
trypsin and variant p.S239C exhibited impaired activity possibly caused by
disulfide mispairing. Surprisingly, variant p.G214R had increased activity on a small chromogenic
peptide substrate but was markedly defective in cleaving bovine β-
casein or the natural CTRC substrates human cationic
trypsinogen and
procarboxypeptidase A1. Mutation p.G214R is analogous to the evolutionary mutation in human mesotrypsin, which rendered this
trypsin isoform resistant to proteinaceous inhibitors and conferred its ability to cleave these inhibitors. Similarly to the mesotrypsin phenotype, CTRC variant p.G214R was inhibited poorly by
eglin C, ecotin, or a CTRC-specific variant of SGPI-2, and it readily cleaved the reactive-site
peptide bonds in
eglin C and ecotin. We conclude that CTRC variants p.R29Q, p.G214R, and p.S239C are risk factors for
chronic pancreatitis. Furthermore, the mesotrypsin-like CTRC variant highlights how the same natural mutation in homologous pancreatic
serine proteases can evolve a new physiological role or lead to pathology, determined by the
biological context of
protease function.